Indefinite Delivery Contract 75N93023D00013
Award Date
9/8/23
Last Date to Order
9/7/30
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
University Of Saskatchewan
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The National Institute of Allergy and Infectious Diseases awarded a multiple-award indefinite delivery contract to the University of Saskatchewan to provide preclinical services supporting the development of therapeutics and diagnostics for infectious diseases. Valued at up to $30 million over seven years, this contract utilizes task orders to procure analytical assay development, cGMP manufacturing, regulatory documentation, and clinical evaluation planning. Areas of performance include the...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $146.3 million single-award Indefinite Delivery Contract to the University of Saskatchewan. The contract covers a 7-year period from July 2024 to July 2031 and includes three main task areas: A. Development and evaluation of small animal models for infectious diseases B. Development and evaluation of non-human primate models for infectious diseases C. Development and evaluation of animal...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to R T I International to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product development...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030. Services will be delivered under five task areas: product...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award Indefinite Delivery Contract to Latham Biopharm Group, Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables ordering under five task areas: product development planning and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to American Type Culture Collection to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables task orders to be issued across five areas: product...
The National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Indefinite Quantity contract to Pharm-Olam, LLC with a potential value of $30,000,000.00 to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. Services will be performed across five task areas: product development planning and evaluation; analytical assay development and product characterization; process development...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027. The contract encompasses a broad scope of work, including in vitro testing and screening, small...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Lovelace Biomedical Research Institute to provide preclinical development support for candidate products and drug development activities for HIV, hepatitis, and tuberculosis. The 7-year, $107.3 million contract covers a range of services across seven task areas, including in vitro screening,...